Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

The Readout LOUD

LISTEN: Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Healthcare Unicorn
Biotech

Amid a market slump, biotech makes room for unicorns

By Damian Garde

Jungeun Lee
Biotech

In the red-hot race to fill biotech jobs, benefits abound

By Jonathan Saltzman — Boston Globe

Biotech

New data for Genentech’s MS drug shows benefit of early treatment

By Kate Sheridan

Business

U.S. crackdown on foreign investments could cool Asia’s desire for U.S. biotech

By Damian Garde

Acute Promyelocytic Leukemia
Biotech

Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy

By Damian Garde

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

FDA Headquarters
Biotech

FDA approves Akcea rare disease drug with a black box warning

By Kate Sheridan

Nick Leschly - Bluebird Bio
Biotech

Surprise! Bluebird Bio’s beta thalassemia gene therapy is already under review in Europe

By Adam Feuerstein

The Readout LOUD

LISTEN: Nobel snubs, millennial founders, and a new kind of lightning round

By Rebecca Robbins and Megan Thielking

STAT SPOTLIGHT
Biotech

Startup Spotlight: This Cambridge biotech snagged a deal with Roche without ever making a pitch

By Kate Sheridan

Sarepta - Cambridge
Biotech

Hop, skip, jump. Sarepta’s Duchenne gene therapy delivers early muscle function improvements

By Adam Feuerstein

Biotech

New data shows Genentech’s potential competitor for Spinraza inching forward

By Kate Sheridan

Ginkgo Bioworks 02
Biotech

In the booming field of synthetic biology, a back-end business reinvents itself

By Rebecca Robbins

Stock Market
Biotech

The biotech scorecard for the fourth quarter: 12 make-or-break industry events to watch

By Adam Feuerstein and Damian Garde

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Lab tests
Biotech

Momenta lays off half of its employees, including key executives

By Jonathan Saltzman — Boston Globe

STAT SPOTLIGHT
Biotech

Startup Spotlight: How funding from the FDA is helping this Boston biotech fly under the radar

By Kate Sheridan

Regeneron
Biotech

Regeneron, with a new drug, tries to elbow its way into a crowded immunotherapy market

By Damian Garde

Business

Pharma tries to cash in on migraine market by making new drugs free, for now

By Damian Garde

Mail bag
Biotech

You have questions about how to best analyze clinical trials. We have answers

By Adam Feuerstein and Sharon Begley

The Readout LOUD

LISTEN: A fish oil epiphany, VC monopolies, and ketamine clinics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Dr. John Maraganore
Biotech

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

By Andrew Joseph

STAT Live

Webinar archive: How to interpret clinical trial results like a pro

By Sharon Begley and Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Fish oil capsules
Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

FDA; Drug Administration campus
Biotech

Sarepta’s gene therapy program for Duchenne resumes after clinical trial hold lifted

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy